Potential involvement of S100B in the protective effects of a serotonin-1a agonist on ethanol-treated astrocytes.
Previously, this laboratory found that the offspring of rats that consumed ethanol on a chronic basis prior to parturition exhibited a significant reduction in serotonin (5-HT) neurons and in astrocytes proximal to these neurons. This laboratory also showed that maternal treatment with a 5-HT(1A) agonist during the latter part of gestation prevented the reduction of 5-HT neurons and most of the astrocyte abnormalities. The present in vitro studies extended our prior in vivo work by examining the potential involvement of S100B with the protective effects of a 5-HT(1A) agonist, i.e., buspirone, on astrocytes. Astrocyte cultures were either maintained in chemically defined media in the presence and absence of ethanol and buspirone or in conditioned media that was generated by ethanol- and buspirone-treated astrocytes. A mouse monoclonal antibody to S100B was used to assess the potential involvement of S100B with the protective effects of buspirone. Additional in vitro studies measured the direct effects of S100B and ethanol on astrocyte proliferation. These investigations demonstrate that in vitro ethanol exposure reduces the number of astrocytes, and that treatment with the 5-HT(1A) agonist buspirone prevents the ethanol-associated reduction in astrocyte number. The protective effects of buspirone appear to be mediated by factors that are secreted by astrocytes; such factors likely include S100B. In addition, added S100B prevents an ethanol-associated reduction in [(3)H]-thymidine incorporation into proliferating astrocytes.
Eriksen
J L
JL
Division of Molecular & Cellular Biochemistry, Department of Cell Biology, Neurobiology, and Anatomy, Loyola University Stritch School of Medicine, Maywood, IL 60153, USA.
Druse
M J
MJ
D000818:Animals; D000911:Antibodies, Monoclonal; D001253:Astrocytes / Q000737:chemistry / Q000166:cytology / Q000378:metabolism*; D002065:Buspirone / Q000494:pharmacology*; D002135:Calcium-Binding Proteins / Q000032:analysis / Q000276:immunology / Q000378:metabolism*; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D000697:Central Nervous System Stimulants / Q000494:pharmacology*; D017077:Culture Media, Conditioned / Q000494:pharmacology; D000431:Ethanol / Q000494:pharmacology*; D005260:Female; D009414:Nerve Growth Factors / Q000032:analysis / Q000276:immunology / Q000378:metabolism*; D011247:Pregnancy; D051381:Rats; D017207:Rats, Sprague-Dawley; D011985:Receptors, Serotonin / Q000378:metabolism; D044263:Receptors, Serotonin, 5-HT1; D064568:S100 Calcium Binding Protein beta Subunit; D009418:S100 Proteins; D017366:Serotonin Receptor Agonists / Q000494:pharmacology*; D013936:Thymidine / Q000493:pharmacokinetics; D014316:Tritium / Q000493:pharmacokinetics
D000911:Antibodies, Monoclonal; D002135:Calcium-Binding Proteins; D000697:Central Nervous System Stimulants; D017077:Culture Media, Conditioned; D009414:Nerve Growth Factors; D011985:Receptors, Serotonin; D044263:Receptors, Serotonin, 5-HT1; D064568:S100 Calcium Binding Protein beta Subunit; D009418:S100 Proteins; C579159:S100b protein, mouse; C579158:S100b protein, rat; D017366:Serotonin Receptor Agonists; D014316:Tritium; D000431:Ethanol; D002065:Buspirone; D013936:Thymidine